Exploiting convergent phenotypes to derive a pan-cancer cisplatin response gene expression signature.
Journal
NPJ precision oncology
ISSN: 2397-768X
Titre abrégé: NPJ Precis Oncol
Pays: England
ID NLM: 101708166
Informations de publication
Date de publication:
19 Apr 2023
19 Apr 2023
Historique:
received:
30
09
2022
accepted:
21
03
2023
medline:
20
4
2023
pubmed:
20
4
2023
entrez:
19
04
2023
Statut:
epublish
Résumé
Precision medicine offers remarkable potential for the treatment of cancer, but is largely focused on tumors that harbor actionable mutations. Gene expression signatures can expand the scope of precision medicine by predicting response to traditional (cytotoxic) chemotherapy agents without relying on changes in mutational status. We present a new signature extraction method, inspired by the principle of convergent phenotypes, which states that tumors with disparate genetic backgrounds may evolve similar phenotypes independently. This evolutionary-informed method can be utilized to produce consensus signatures predictive of response to over 200 chemotherapeutic drugs found in the Genomics of Drug Sensitivity in Cancer (GDSC) Database. Here, we demonstrate its use by extracting the Cisplatin Response Signature (CisSig). We show that this signature can predict cisplatin response within carcinoma-based cell lines from the GDSC database, and expression of the signatures aligns with clinical trends seen in independent datasets of tumor samples from The Cancer Genome Atlas (TCGA) and Total Cancer Care (TCC) database. Finally, we demonstrate preliminary validation of CisSig for use in muscle-invasive bladder cancer, predicting overall survival in a small cohort of patients who undergo cisplatin-containing chemotherapy. This methodology can be used to produce robust signatures that, with further clinical validation, may be used for the prediction of traditional chemotherapeutic response, dramatically increasing the reach of personalized medicine in cancer.
Identifiants
pubmed: 37076665
doi: 10.1038/s41698-023-00375-y
pii: 10.1038/s41698-023-00375-y
pmc: PMC10115855
doi:
Types de publication
Journal Article
Langues
eng
Pagination
38Subventions
Organisme : NCI NIH HHS
ID : L30 CA162069
Pays : United States
Organisme : NCI NIH HHS
ID : R37 CA244613
Pays : United States
Organisme : NCI NIH HHS
ID : F30 CA257076
Pays : United States
Organisme : NCI NIH HHS
ID : U54 CA274513
Pays : United States
Informations de copyright
© 2023. The Author(s).
Références
Hirsch, F. R. et al. Lung cancer: current therapies and new targeted treatments. Lancet 389, 299–311 (2017).
pubmed: 27574741
doi: 10.1016/S0140-6736(16)30958-8
Solomon, B. J. et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. New Engl. J. Med. 371, 2167–2177 (2014).
pubmed: 25470694
doi: 10.1056/NEJMoa1408440
Prasad, V., De Jesus, K. & Mailankody, S. The high price of anticancer drugs: origins, implications, barriers, solutions. Nat. Rev. Clin. Oncol. 14, 381 (2017).
pubmed: 28290490
doi: 10.1038/nrclinonc.2017.31
Haslam, A., Kim, M. & Prasad, V. Updated estimates of eligibility for and response to genome-targeted oncology drugs among us cancer patients, 2006–2020. Ann. Oncol. 32, 926–932 (2021).
pubmed: 33862157
doi: 10.1016/j.annonc.2021.04.003
Sparano, J. A. et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. New Engl. J. Med. 379, 111–121 (2018).
pubmed: 29860917
doi: 10.1056/NEJMoa1804710
Soliman, H. et al. Mammaprint guides treatment decisions in breast cancer: results of the impact trial. BMC Cancer 20, 81 (2020).
pubmed: 32005181
pmcid: 6995096
doi: 10.1186/s12885-020-6534-z
Scott, J. G. et al. A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study. Lancet Oncol. 18, 202–211 (2017).
pubmed: 27993569
doi: 10.1016/S1470-2045(16)30648-9
Scott, J. G. et al. Pan-cancer prediction of radiotherapy benefit using genomic-adjusted radiation dose (GARD): a cohort-based pooled analysis. Lancet Oncol. 22, 1221–1229 (2021).
pubmed: 34363761
doi: 10.1016/S1470-2045(21)00347-8
Eschrich, S. A. et al. A gene expression model of intrinsic tumor radiosensitivity: prediction of response and prognosis after chemoradiation. Int. J. Radiat. Oncol. Biol. Phys. 75, 489–496 (2009).
pubmed: 19735873
pmcid: 3038688
doi: 10.1016/j.ijrobp.2009.06.014
Torres-Roca, J. F. A molecular assay of tumor radiosensitivity: a roadmap towards biology-based personalized radiation therapy. Pers. Med. 9, 547–557 (2012).
doi: 10.2217/pme.12.55
Nichol, D. et al. Antibiotic collateral sensitivity is contingent on the repeatability of evolution. Nat. Commun. 10, 1–10 (2019).
doi: 10.1038/s41467-018-08098-6
Scarborough, J. A. et al. Identifying states of collateral sensitivity during the evolution of therapeutic resistance in Ewing’s sarcoma. Iscience 23, 101293 (2020).
pubmed: 32623338
pmcid: 7334607
doi: 10.1016/j.isci.2020.101293
Dhawan, A. et al. Collateral sensitivity networks reveal evolutionary instability and novel treatment strategies in ALK mutated non-small cell lung cancer. Sci. Rep. 7, 1–9 (2017).
doi: 10.1038/s41598-017-00791-8
Blount, Z. D., Lenski, R. E. & Losos, J. B. Contingency and determinism in evolution: replaying life’s tape. Science 362, eaam5979 (2018).
pubmed: 30409860
doi: 10.1126/science.aam5979
Barr, M. P. et al. Generation and characterisation of cisplatin-resistant non-small cell lung cancer cell lines displaying a stem-like signature. PLoS ONE 8, e54193 (2013).
pubmed: 23349823
pmcid: 3547914
doi: 10.1371/journal.pone.0054193
Mucaki, E. J., Zhao, J. Z., Lizotte, D. J. & Rogan, P. K. Predicting responses to platin chemotherapy agents with biochemically-inspired machine learning. Signal Transduct. Target. Ther. 4, 1–12 (2019).
pubmed: 30652029
pmcid: 6329797
doi: 10.1038/s41392-018-0034-5
Kim, H. K. et al. A gene expression signature of acquired chemoresistance to cisplatin and fluorouracil combination chemotherapy in gastric cancer patients. PLoS ONE 6, e16694 (2011).
pubmed: 21364753
pmcid: 3041770
doi: 10.1371/journal.pone.0016694
Wei, R. et al. A gene expression signature to predict nucleotide excision repair defects and novel therapeutic approaches. Int. J. Mol. Sci. 22, 5008 (2021).
pubmed: 34066883
pmcid: 8125907
doi: 10.3390/ijms22095008
Sun, J. et al. Large-scale integrated analysis of ovarian cancer tumors and cell lines identifies an individualized gene expression signature for predicting response to platinum-based chemotherapy. Cell Death Dis. 10, 1–12 (2019).
doi: 10.1038/s41419-019-1874-9
Buffa, F., Harris, A., West, C. & Miller, C. Large meta-analysis of multiple cancers reveals a common, compact and highly prognostic hypoxia metagene. Br. J. Cancer 102, 428 (2010).
pubmed: 20087356
pmcid: 2816644
doi: 10.1038/sj.bjc.6605450
Eustace, A. et al. A 26-gene hypoxia signature predicts benefit from hypoxia-modifying therapy in laryngeal cancer but not bladder cancer. Clin. Cancer Res. 19, 4879–4888 (2013).
pubmed: 23820108
pmcid: 3797516
doi: 10.1158/1078-0432.CCR-13-0542
Yang, L. et al. A gene signature for selecting benefit from hypoxia modification of radiotherapy for high-risk bladder cancer patients. Clin. Cancer Res. 23, 4761–4768 (2017).
pubmed: 28400426
doi: 10.1158/1078-0432.CCR-17-0038
Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47–e47 (2015).
pubmed: 25605792
pmcid: 4402510
doi: 10.1093/nar/gkv007
Tusher, V., Tibshirani, R. & Chu, C. Significance analysis of microarrays applied to ionizing radiation response. Proc. Natl Acad. Sci. USA 98, 5116–5121 (2001).
pubmed: 11309499
pmcid: 33173
doi: 10.1073/pnas.091062498
Pollard, K. S., Dudoit, S. & van der Laan, M. J. In Bioinformatics and Computational Biology Solutions Using R and Bioconductor 249–271 (Springer, 2005).
Dhawan, A., Barberis, A., Cheng, W.-C. & Buffa, F. sigQC: Quality Control Metrics for Gene Signatures. R package version 0.1.21 (2018).
Dhawan, A. et al. Guidelines for using sigQC for systematic evaluation of gene signatures. Nat. Protoc. 14, 1377 (2019).
pubmed: 30971781
doi: 10.1038/s41596-019-0136-8
Venet, D., Dumont, J. E. & Detours, V. Most random gene expression signatures are significantly associated with breast cancer outcome. PLoS Comput. Biol. 7, e1002240 (2011).
pubmed: 22028643
pmcid: 3197658
doi: 10.1371/journal.pcbi.1002240
Azuaje, F. Computational models for predicting drug responses in cancer research. Brief. Bioinforma. 18, 820–829 (2017).
Jin, S. et al. Cell division cycle 7 is a potential therapeutic target in oral squamous cell carcinoma and is regulated by E2F1. J. Mol. Med. 96, 513–525 (2018).
pubmed: 29713760
doi: 10.1007/s00109-018-1636-7
Wang, C. et al. Inducing and exploiting vulnerabilities for the treatment of liver cancer. Nature 574, 268–272 (2019).
pubmed: 31578521
pmcid: 6858884
doi: 10.1038/s41586-019-1607-3
Li, L. et al. Expression of the b3 subunit of Na+/K+-ATPase is increased in gastric cancer and regulates gastric cancer cell progression and prognosis via the PI3/AKT pathway. Oncotarget 8, 84285 (2017).
pubmed: 29137423
pmcid: 5663595
doi: 10.18632/oncotarget.20894
Lu, M. et al. RNAi-mediated downregulation of FKBP14 suppresses the growth of human ovarian cancer cells. Oncol. Res. 23, 267 (2016).
pubmed: 27131312
pmcid: 7838629
doi: 10.3727/096504016X14549667333963
Tomkiewicz, C. et al. A head and neck cancer tumor response-specific gene signature for cisplatin, 5-fluorouracil induction chemotherapy fails with added taxanes. PLoS One 7, e47170 (2012).
pubmed: 23056603
pmcid: 3467249
doi: 10.1371/journal.pone.0047170
Yang, W. et al. Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res. 41, D955–D961 (2013).
pubmed: 23180760
doi: 10.1093/nar/gks1111
Irizarry, R. A. et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4, 249–264 (2003).
pubmed: 12925520
doi: 10.1093/biostatistics/4.2.249
Iorio, F. et al. A landscape of pharmacogenomic interactions in cancer. Cell 166, 740–754 (2016).
pubmed: 27397505
pmcid: 4967469
doi: 10.1016/j.cell.2016.06.017
Vis, D. J. et al. Multilevel models improve precision and speed of IC50 estimates. Pharmacogenomics 17, 691–700 (2016).
pubmed: 27180993
doi: 10.2217/pgs.16.15
Samur, M. K. RTCGAToolbox: a new tool for exporting TCGA firehose data. PLoS ONE 9, e106397 (2014).
pubmed: 25181531
pmcid: 4152273
doi: 10.1371/journal.pone.0106397
Fenstermacher, D. A., Wenham, R. M., Rollison, D. E. & Dalton, W. S. Implementing personalized medicine in a cancer center. Cancer J. 17, 528 (2011).
pubmed: 22157297
pmcid: 3240816
doi: 10.1097/PPO.0b013e318238216e
Dalton, W. S. The “total cancer care” concept: linking technology and health care. Cancer Control 12, 140–141 (2005).
pubmed: 15855897
doi: 10.1177/107327480501200211
Welsh, E. A., Eschrich, S. A., Berglund, A. E. & Fenstermacher, D. A. Iterative rank-order normalization of gene expression microarray data. BMC Bioinforma. 14, 1–11 (2013).
doi: 10.1186/1471-2105-14-153
Baccarella, A., Williams, C. R., Parrish, J. Z. & Kim, C. C. Empirical assessment of the impact of sample number and read depth on RNA-seq analysis workflow performance. BMC Bioinforma. 19, 423 (2018).
doi: 10.1186/s12859-018-2445-2